Cited by 442Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchNeuroinflammation and Neurodegeneration Mechanisms

The DOI matches its Crossref record; 281 of the 286 references it cites were found in a registry or an index; none of the 200 sources its claims cite is checked for support yet.

The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease

Open access
Ferreira, Sergio T., Klein, William L.·2011·Neurobiology of Learning and Memory

Abstract

Alzheimer's disease (AD) is the 3rd most costly disease and the leading cause of dementia. It can linger for many years, but ultimately is fatal, the 6th leading cause of death. Alzheimer's disease (AD) is fatal and affected individuals can sometimes linger many years. Current treatments are palliative and transient, not disease modifying. This article reviews progress in the search to identify the primary AD-causing toxins. We summarize the shift from an initial focus on amyloid plaques to the contemporary concept that AD memory failure is caused by small soluble oligomers of the Aβ peptide, toxins that target and disrupt particular synapses. Evidence is presented that links Aβ oligomers to pathogenesis in animal models and humans, with reference to seminal discoveries from cell biology and new ideas concerning pathogenic mechanisms, including relationships to diabetes and Fragile X. These findings have established the oligomer hypothesis as a new molecular basis for the cause, diagnosis, and treatment of AD.

Overview

AI snapshot

Written from the paper’s full text.

TL;DR

This review argues that soluble Aβ oligomers, rather than insoluble amyloid plaques, are the primary synaptotoxic agents causing early memory failure in Alzheimer’s disease. It synthesizes cell, animal, and human evidence linking oligomers to synaptic plasticity disruption, synapse loss, tau pathology, insulin resistance, and candidate therapeutic strategies.

Key findings

  • Aβ oligomers inhibit long-term potentiation (LTP) within minutes without affecting baseline excitability, and memory loss in APP transgenic mice can be reversed by anti-Aβ antibodies without removing amyloid plaques.
  • Oligomers accumulate in AD-affected human brain and in essentially all transgenic AD models examined; synthetic and brain-derived oligomers show biochemical identity, and oligomer size remains debated (dimers–tetramers vs. 12mers/24mers), with SDS-stable 12mers linked to memory failure in one model.
  • Oligomers target synapses: >90% co-localization with post-synaptic marker PSD-95; 50–85% of hippocampal neurons bind oligomers while others are spared; binding is associated with tau hyperphosphorylation, insulin receptor redistribution, spine loss, and oxidative stress.
  • AD is discussed as a brain-specific form of diabetes (“type 3 diabetes”): Aβ oligomers induce insulin resistance, and intranasal insulin improves cognition in early AD at higher doses, consistent with insulin resistance.

Methods

  • Narrative review of the literature, not a primary experimental study; it synthesizes findings from cell biology, animal models, human AD brain/CSF, and human genetics.
  • Evidence discussed includes synthetic and brain-derived Aβ oligomers, transgenic mouse/rat/C. elegans/Drosophila models, electrophysiology (LTP/LTD), imaging, biochemical assays, and human clinical/ biomarker studies.
  • Main analysis is qualitative synthesis; Tables 2 and 3 summarize synapse-specific and more generalized neuronal effects of Aβ oligomers.

Limitations

  • Stated: the pathogenic oligomer size is uncertain; detection is limited by SDS-PAGE/Western blot, antibody choice, heat denaturation, and detergent; not all oligomers are toxic; nomenclature is confusing; why toxic oligomers accumulate in sporadic AD is largely unknown; intracellular vs. extracellular localization is unresolved; PrPC involvement is debated; synthetic oligomers can clump at high concentrations.
  • Stated: published studies use different oligomer preparations, concentrations, incubation times, brain regions, and culture maturation stages, complicating comparison.
  • Evident: as a narrative review, it lacks a systematic search strategy, formal quality appraisal, or meta-analysis, and presents an author-framed argument favoring the oligomer hypothesis.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1016/j.nlm.2011.08.003

Cites

281 of 281 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

0 of 200 cited sources checked · 0 supported · 0 flagged

  • It may state two separate claims as one. 69
  • Probably not a substantial claim. 20
86 of 86
  • The paper relies on this without support.

    Early AD is largely a disease of memory formation, and memory dysfunction is the primary symptom bringing patients to physicians.

    “the symptom that first brings patients to a physician is a troubling inability to form new memories, and early AD is largely regarded as a disease of memory formation.”
  • The paper relies on this without support.

    AD can be attributed to a single disease-initiating cytotoxin, albeit one likely elicited by multiple factors.

    “This article reviews progress in the search for primary AD-causing toxins.”
    “If we could regard AD as having a single disease-initiating cytotoxin (albeit one likely elicited by multiple factors), its action minimally must provide a basis for memory dysfunction.”
  • The authors state this as an assumption.

    Aβ oligomers act from the extracellular milieu.

    “A premise for investigating the effects of exogenous oligomers on memory and neuropathology is that oligomers presumably act from the extracellular milieu.”
3 of 3

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

2 retracted

Flagged first, then by citations

Show all 286 references

5 of the 286 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

See all 442

Metadata

Authors
Ferreira, S. T., & Klein, W. L.
Affiliations
  • Universidade Federal do Rio de Janeiro (BR)
  • Northwestern University (US)
Corresponding author
Klein, William L.
Venue
Neurobiology of Learning and Memory
Publisher
Elsevier BV
Published
2011-11
Volume
96
Issue
4
Pages
529-543
ISSN
1074-7427 (ISSN-L)
OpenAlex
W2051268743
Cited by
442
References
286
Citations by year
2026: 11 · 2025: 19 · 2024: 22 · 2023: 24 · 2022: 37 · 2021: 28 · 2020: 35 · 2019: 23 · 2018: 44 · 2017: 41 · 2016: 33 · 2015: 35 · 2014: 38 · 2013: 24 · 2012: 26
FWCI
3.13
Type
journal article
Language
en
Open access
Locations
  • Neurobiology of Learning and Memory (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
National Institute on Aging (R01AG022547, R01AG029460, R01AG018877)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords
Alzheimer's disease, amyloid-beta oligomers, memory loss, amyloid plaques, pathogenesis, diabetes mellitus, fragile X syndrome, animal models of Alzheimer's disease, Alzheimer's disease treatment
MeSH terms
Alzheimer Disease, Brain, Humans, Memory Disorders, Neurons, Synapses, Amyloid beta-Peptides, Plaque, Amyloid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review